Constantine Saroukos - Takeda Pharmaceutical CFO Director
| TAK Stock | USD 13.62 0.05 0.37% |
Insider
Constantine Saroukos is CFO Director of Takeda Pharmaceutical Co
| Age | 53 |
| Address | 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 |
| Phone | 81 3 3278-2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has Return on Asset of 0.0278 % which means that on every $100 spent on assets, it made $0.0278 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0415 %, implying that it generated $0.0415 on every 100 dollars invested. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.03. The value of Return On Capital Employed is expected to slide to 0.02. At this time, Takeda Pharmaceutical's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 15.9 T this year, although the value of Non Current Liabilities Other will most likely fall to about 435.2 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| William Price | Zoetis Inc | N/A | |
| Racquel Mason | Elanco Animal Health | 50 | |
| Marlo Manning | Collegium Pharmaceutical | N/A | |
| Eiry MD | Neurocrine Biosciences | 60 | |
| Julien Meissonnier | Catalent | N/A | |
| Roy MD | Pacira BioSciences, | 62 | |
| Marvin White | Emergent Biosolutions | 58 | |
| Steven Miller | Bausch Health Companies | 31 | |
| Christian Dargel | Evotec SE ADR | 53 | |
| Tamara Rogers | Haleon plc | 54 | |
| MBA MBA | Evotec SE ADR | 54 | |
| Christopher Coughlin | Prestige Brand Holdings | 67 | |
| Robert Spurr | Bausch Health Companies | 51 | |
| Teri Lyng | Haleon plc | 62 | |
| III MD | SIGA Technologies | 55 | |
| Karen Santiago | Catalent | 53 | |
| MD FACC | Esperion Therapeutics | 59 | |
| David Bayles | Viatris | N/A | |
| Karen Smith | Emergent Biosolutions | 52 | |
| Abhay Nayak | Zoetis Inc | 32 | |
| Betty Swartz | Esperion Therapeutics | N/A | |
Management Performance
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Giles Platford, President Unit | ||
| Ian Clark, Independent Director | ||
| Constantine Saroukos, CFO Director | ||
| Salvatore MD, Member Policy | ||
| Milano Furuta, Chief Officer | ||
| Masami Iijima, Independent Director | ||
| Christophe Weber, President, Chief Executive Officer, Representative Director | ||
| Masahiro Sakane, Independent Chairman of the Executive Board | ||
| Seigo Izumo, Chair Board | ||
| Olivier Bohuon, Independent Director | ||
| Gabriele Ricci, Chief Officer | ||
| Ken Araki, Vice Department | ||
| JeanLuc Butel, Independent Director | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Senior Department | ||
| Michel Orsinger, Independent Director | ||
| Shiro Kuniya, Independent Director | ||
| Christopher OReilly, Global Finance | ||
| Toshiyuki Shiga, Independent Director | ||
| Steven Gillis, Independent Director | ||
| Mwana Lugogo, Chief Officer | ||
| Lauren Duprey, Chief Officer | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller | ||
| Masato Iwasaki, President of Japan Pharma Business Unit, Director | ||
| Emiko Higashi, Independent Director | ||
| Andrew Plump, President of Research & Development, Vice President of Subsidiary, Director | ||
| Costa Saroukos, Chief Financial Officer, Director | ||
| Yoshiaki Fujimori, Independent Director | ||
| Koji Hatsukawa, Independent Director | ||
| Yoshihiro Nakagawa, Global Counsel |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0415 | ||||
| Return On Asset | 0.0278 | ||||
| Profit Margin | 0.06 % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 70.22 B | ||||
| Shares Outstanding | 3.17 B | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 2.40 % | ||||
| Number Of Shares Shorted | 5.66 M | ||||
| Price To Earning | 27.57 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.6 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.